Fibromyalgia Screening for Accurate Lupus Treatment Efficacy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clinical drug trials for systemic lupus erythematosus (SLE) have a high failure rate due to the inclusion of patients with concomitant fibromyalgia, which complicates symptom assessment and masks the therapeutic benefits of medications, as fibromyalgia symptoms overlap with lupus symptoms, leading to inaccurate measurement of treatment efficacy.
Innovation Solution
Implementing methods and systems to diagnose concomitant fibromyalgia in lupus patients using the 2010 and 2016 American College of Rheumatology criteria, and refining assessment tools like SELENA-SLEDAI and BILAG to exclude patients with fibromyalgia, ensuring accurate evaluation of lupus treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If fibromyalgia patients are included in lupus clinical trials, then sample size and patient diversity are improved, but measurement precision of treatment efficacy deteriorates due to overlapping symptoms
Solution Approach 1:
The patent segments the patient population into distinct groups: lupus-only patients and lupus-plus-fibromyalgia patients. This segmentation allows separate analysis of treatment effects on each group, preventing the confounding of symptom sources. The assessment tools are also segmented to evaluate lupus-specific symptoms separately from fibromyalgia symptoms.
Solution Approach 2:
The patent introduces fibromyalgia screening as an intermediary step in the patient selection and assessment process. By implementing screening tools (such as the Fibromyalgia Impact Questionnaire or ACR criteria) before enrollment, the system identifies and stratifies patients with concomitant fibromyalgia, allowing researchers to account for this comorbidity in the analysis.
2Measurement precision
If assessment tools are refined to exclude fibromyalgia patients, then measurement precision is improved, but patient diversity and sample representativeness worsen
Solution Approach 1:
The patent implements dynamic assessment strategies where the interpretation of symptom scores varies based on the patient's fibromyalgia status. Assessment tools are adapted dynamically: for lupus-only patients, standard lupus activity indices are used; for patients with concomitant fibromyalgia, adjusted interpretation criteria are applied that account for the expected contribution of fibromyalgia to certain symptoms.
Solution Approach 2:
The patent applies different assessment criteria and interpretation standards to different patient subgroups. Instead of a uniform exclusion criterion, the system applies local quality control by tailoring the assessment approach to each patient's specific comorbidity profile, allowing precise measurement within each subgroup while maintaining overall sample diversity.
3Ease of operation
If fibromyalgia is not screened out, then patient enrollment is simplified, but treatment efficacy evaluation accuracy deteriorates due to symptom overlap
Solution Approach 1:
The patent implements preliminary fibromyalgia screening during the patient enrollment phase using validated questionnaires and criteria. This preliminary action identifies patients with concomitant fibromyalgia before they enter the trial, allowing researchers to stratify the sample and apply appropriate analysis methods from the outset, rather than attempting to address the issue during data analysis.
4Adaptability or versatility
If concomitant fibromyalgia is present, then real-world patient representation is improved, but disease activity measurement accuracy worsens due to disease amplification
Solution Approach 1:
The patent incorporates feedback mechanisms where fibromyalgia screening results inform the interpretation of disease activity measurements throughout the trial. The system continuously monitors symptom patterns and uses the known fibromyalgia status of each patient to adjust the interpretation of disease activity scores, creating a feedback loop that maintains measurement accuracy despite the presence of comorbidity.
Data Source
AI summary
The present invention comprises excluding fibromyalgia patients in clinical studies for patients with lupus, treating the patients for lupus, and increasing the effectiveness of the lupus treatment by excluding patients with fibromyalgia. This makes the SELENA-SLEDAI and BILAG unreliable instruments for assessing the effectiveness of lupus interventions.